A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation.

Blood20.30
Volume: 135, Issue: 24, Pages: 2182 - 2191
Published: Jun 11, 2020
Abstract
Programmed cell death-1 (PD-1)/programmed death ligand-1 blockade may potentially augment graft-vs-tumor effects following allogeneic hematopoietic cell transplantation (alloHCT), but retrospective studies of anti-PD-1 therapy reported substantial toxicity from graft-versus-host-disease (GVHD). Here, we report the results of a prospective clinical trial of PD-1 blockade for relapsed hematologic malignancies (HMs) after alloHCT (NCT01822509). The...
Paper Details
Title
A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation.
Published Date
Jun 11, 2020
Journal
Volume
135
Issue
24
Pages
2182 - 2191
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.